Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment

The aim of this study was to define the factors that -affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) -patients treated with second-line chemotherapy. We retrospectively reviewed the data of 59 patients with MGC or GEJ adeno...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta gastro-enterologica belgica 2016-04, Vol.79 (2), p.211-215
Hauptverfasser:	Turkmen, Esma, Erdogan, Bulent, Kodaz, Hilmi, Hacibekiroglu, Ilhan, Onal, Yılmaz, Uzunoglu, Sernaz, Kilic, Nilufer, Cicin, Irfan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - secondary Adult Aged Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - analogs & derivatives Camptothecin - therapeutic use Capecitabine - therapeutic use Cisplatin - administration & dosage Disease Progression Disease-Free Survival Epirubicin - administration & dosage Esophagogastric Junction - pathology Female Fluorouracil - administration & dosage Fluorouracil - therapeutic use Humans Leucovorin - therapeutic use Male Middle Aged Neoplasm Recurrence, Local - drug therapy Organoplatinum Compounds - therapeutic use Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - secondary Retrospective Studies Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Survival Rate Taxoids - administration & dosage Taxoids - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of this study was to define the factors that -affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) -patients treated with second-line chemotherapy. We retrospectively reviewed the data of 59 patients with MGC or GEJ adenocarcinoma who received second-line treatment. The median age was 54 years old (26-77). Response to second-line treatment was strongly associated with disease control with first-line treatment (p
ISSN:	1784-3227